14 Feb , 2025 By : Debdeep Gupta
At around 10:40 AM, the stock was trading at Rs 875.50 per share on the NSE, down 10.21 percent after the firm reported a 37.75 percent decline in consolidated net profit in the December quarter. The stock had tanked 19.99 percent to settle at Rs 973.40 on the BSE on Thursday. Intra-day, it hit the lower circuit limit of Rs 973.35. At the NSE, it cracked 19.99 percent to Rs 975.05 -- the lower circuit limit.
The company's market valuation eroded nearly Rs 6,000 crore in two days to Rs 15,722.26 crore on the NSE on February 14. In traded volume terms, 44.90 lakh shares of the firm were traded at the NSE during the day.
The analysts at the domestic brokerage Dolat Capital said "Natco is facing challenges in base business growth ex Revlimid
as the ramp up across the segments is not in line with expectations, which has also led to significant erosion of core margins ex Revlimid."
"FY26 sales growth will depend on Revlimid price erosion. The company expects a significant drop in FY27 earnings due to
increased competition in Revlimid sales post-patent expiry," it added.
NATCO Pharma on February 12 reported a 37.75 percent decline in consolidated net profit to Rs 132.4 crore in the December quarter, hit by a drop in formulations exports. The company had posted a consolidated net profit of Rs 212.7 crore in the December quarter of the previous fiscal year, NATCO Pharma said in a regulatory filing.
0 Comment